Triple

T1169407
Position Surface form Disambiguated ID Type / Status
Subject Spinraza E24879 entity
Predicate developedBy P73 FINISHED
Object Biogen E3807 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Biogen | Statement: [Spinraza, developedBy, Biogen]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Biogen
Context triple: [Spinraza, developedBy, Biogen]
  • A. Biogen chosen
    Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
  • B. Eisai and Biogen
    Eisai and Biogen are pharmaceutical companies that collaborate on developing innovative therapies, particularly in the field of neurodegenerative diseases such as Alzheimer’s.
  • C. Eisai
    Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
  • D. Eli Lilly and Company
    Eli Lilly and Company is a major American pharmaceutical corporation known for developing and manufacturing a wide range of prescription medicines, including treatments for diabetes, cancer, and mental health disorders.
  • E. Genentech
    Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a494082a7c819095004f423f294a64 completed March 1, 2026, 7:31 p.m.
NER Named-entity recognition batch_69a4bce821b481908bc278a3fa7973f4 completed March 1, 2026, 10:25 p.m.
NED1 Entity disambiguation (via context triple) batch_69ac8311ba6481908aaca4c1e9d8b78f completed March 7, 2026, 7:57 p.m.
Created at: March 1, 2026, 7:45 p.m.